Your browser is no longer supported. Please, upgrade your browser.
Settings
CLMT Calumet Specialty Products Partners, L.P. daily Stock Chart
CLMT [NASD]
Calumet Specialty Products Partners, L.P.
Index- P/E- EPS (ttm)-1.39 Insider Own0.10% Shs Outstand79.15M Perf Week1.27%
Market Cap633.20M Forward P/E- EPS next Y-1.04 Insider Trans226.46% Shs Float60.36M Perf Month3.90%
Income-107.60M PEG- EPS next Q0.26 Inst Own9.90% Short Float1.06% Perf Quarter53.85%
Sales3.88B P/S0.16 EPS this Y-104.10% Inst Trans-25.31% Short Ratio1.26 Perf Half Y116.22%
Book/sh2.68 P/B2.99 EPS next Y-458.60% ROA-3.90% Target Price8.00 Perf Year102.53%
Cash/sh0.34 P/C23.80 EPS next 5Y10.00% ROE-48.50% 52W Range2.79 - 9.10 Perf YTD100.00%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-7.50% 52W High-12.09% Beta1.23
Dividend %- Quick Ratio0.60 Sales past 5Y2.80% Gross Margin12.60% 52W Low186.74% ATR0.32
Employees2000 Current Ratio1.40 Sales Q/Q6.00% Oper. Margin1.70% RSI (14)51.36 Volatility4.32% 4.04%
OptionableYes Debt/Eq9.57 EPS Q/Q106.30% Profit Margin-2.80% Rel Volume0.30 Prev Close7.90
ShortableYes LT Debt/Eq9.55 EarningsNov 02 BMO Payout- Avg Volume509.12K Price8.00
Recom2.80 SMA20-3.07% SMA505.51% SMA20060.24% Volume153,148 Change1.27%
Sep-05-17Downgrade Janney Buy → Neutral
Aug-14-17Upgrade Janney Neutral → Buy
May-10-17Upgrade Wells Fargo Market Perform → Outperform
Mar-24-17Downgrade Credit Suisse Neutral → Underperform
Nov-04-16Upgrade Credit Suisse Underperform → Neutral
Sep-09-16Initiated FBR Capital Mkt Perform $6
May-06-16Reiterated RBC Capital Mkts Sector Perform $7 → $5
May-05-16Upgrade DA Davidson Underperform → Neutral $5
May-05-16Reiterated Cowen Market Perform $10 → $5
Apr-22-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-19-16Downgrade DA Davidson Buy → Underperform $5
Apr-18-16Reiterated Scotia Howard Weil Sector Underperform $19 → $5
Apr-18-16Reiterated Cowen Market Perform $23 → $10
Apr-18-16Downgrade Wells Fargo Outperform → Market Perform
Apr-18-16Downgrade Raymond James Mkt Perform → Underperform
Apr-11-16Downgrade Credit Suisse Outperform → Underperform
Feb-19-16Downgrade Credit Suisse Outperform → Neutral
Feb-18-16Reiterated RBC Capital Mkts Outperform $27 → $22
Feb-18-16Reiterated Cowen Buy $32 → $23
Nov-23-15Initiated Goldman Neutral
Oct-17-17 01:22PM  Top MLP Losers in the Week Ending October 13 Market Realist
Oct-16-17 05:37PM  Why Calumet Specialty Products Partners LP (CLMT) Could Be A Buy Simply Wall St.
Oct-03-17 02:20PM  Better Buy: Calumet Specialty Products Partners LP vs. Delek US Holdings, Inc. Motley Fool
Oct-02-17 09:00AM  Calumet Specialty Products Partners, L.P. To Attend Upcoming Deutsche Bank 25th Annual Leveraged Finance Conference PR Newswire
Sep-21-17 02:21PM  Better Buy: Calumet Specialty Products Partners LP vs. Valero Energy Motley Fool
02:09PM  Why Income Investors May Not Find ALDWs Yield Attractive Market Realist
Sep-20-17 01:08PM  Calumet Specialty Products Partners LP :CLMT-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube
Sep-19-17 07:37AM  Analysts Recommendations for Calumet Specialty Market Realist
Sep-18-17 10:38AM  Calumet Specialty Products Short Interest Rose Market Realist
09:10AM  Are Institutional Investors Bearish on Calumet Specialty? Market Realist
08:06AM  Calumet Specialtys Leverage Has Fallen Significantly Market Realist
Sep-15-17 04:36PM  Analyzing Calumet Specialtys Distributable Cash Flows Market Realist
03:06PM  Whats Changing in Calumet Specialtys Businesses? Market Realist
01:26PM  Calumet Specialty Stock Has Doubled in 2017 Market Realist
Sep-14-17 09:45AM  How to Trade the Oil Rally with ETFs & Stocks Zacks
Sep-12-17 04:33PM  How Calumet Specialty Products Partners LP Makes Most of Its Money Motley Fool
10:07AM  MLP Rating Updates for the Week Ended September 8 Market Realist
Sep-07-17 08:44AM  3 Reasons Why Calumet Specialty Products (CLMT) is a Great Momentum Stock Zacks
Sep-06-17 05:40PM  5 Oil Stocks that Outperformed in August Zacks
Sep-05-17 01:36PM  Downstream MLPs among Top MLP Gainers Last Week Market Realist
12:01PM  Do Calumets Technical Indicators Hint Further Price Rise? Market Realist
Sep-01-17 07:05PM  Oil and Gas Stock Roundup: Harvey Looms Large Motley Fool
Aug-24-17 12:55PM  Why US Crude Oil Production Is Bearish for Oil Prices Market Realist
08:44AM  Why Calumet Specialty Products (CLMT) Could Be Positioned for a Surge Zacks
Aug-23-17 08:41AM  Zacks.com featured highlights: Glu Mobile, Calumet Specialty Products Partners, The Bancorp, Immunomedics and Hudbay Minerals Zacks
Aug-22-17 12:10PM  These MLPs Came out on Top on August 18 Market Realist
Aug-21-17 11:21AM  These Energy Stocks Rose the Most Last Week Market Realist
10:57AM  US Dollar Supported Crude Oil Prices Last Week Market Realist
Aug-18-17 07:05PM  Oil and Gas Stock Roundup: These Strategy Updates Fueled Some Massive Moves Motley Fool +6.50%
Aug-17-17 10:00AM  Why Is US Crude Oil Production at a 2-Year High? Market Realist
Aug-16-17 05:36PM  Calumet Specialty Has Risen More Than 60% in 2017: Whats Next? Market Realist -5.34%
04:06PM  Are Calumet Specialty Products Earnings Improving? Market Realist
02:22PM  Calumet Specialtys Superior Refinery Sale: Key Highlights Market Realist
Aug-15-17 04:30PM  Why Wynn Resorts, Extreme Networks, and Calumet Specialty Products Partners Jumped Today Motley Fool +9.17%
Aug-14-17 08:55AM  Calumet Specialty Products Partners, L.P. Announces Agreement to Sell Superior Refinery and Related Assets PR Newswire +10.09%
Aug-13-17 12:05AM  Edited Transcript of CLMT earnings conference call or presentation 4-Aug-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-07-17 05:00PM  Calumet Specialty Products Partners, L.P. To Attend Upcoming Goldman Sachs Power, Utilities, MLPs, and Pipelines Conference PR Newswire
Aug-04-17 04:04PM  Calumet Specialty Products Partners Q2 Earnings Are a Testament to Its CEO's Turnaround Plan Motley Fool
07:00AM  Calumet Specialty Products Partners, L.P. Reports Second Quarter 2017 Results PR Newswire
06:30AM  Investor Network: Calumet Specialty Products Partners, L.P. to Host Earnings Call ACCESSWIRE
Jul-31-17 10:42AM  What Lies ahead for Refining MLPs after Their 2Q17 Results? Market Realist
Jul-25-17 10:37AM  Analysts Seem Uncertain about Refining MLPs Future Market Realist
09:07AM  Short Interest In ALDW, CVRR, and CLMT Falls Market Realist
08:11AM  Who Were the Top Energy Gainers Last Week? Market Realist
07:37AM  Institutional Investors Views on Refining MLPs Market Realist
Jul-24-17 10:38AM  Why CLMT and ALDW Have Risen despite Sector Weakness Market Realist
09:09AM  A Look at Refining MLPs Capital Expenditure Trends Market Realist
07:40AM  Could CVR Refining Pay Distributions in 2Q17? Market Realist
Jul-21-17 04:36PM  ALDW, CVRR, CLMT: Could Refining Margins Improve In 2Q17? Market Realist
03:02PM  ALDW and CLMT Are Expected to Report Higher 2Q17 Earnings Market Realist
Jul-19-17 08:21AM  5 Things Calumet Specialty Products Partners' Management Thinks You Should Know Motley Fool +5.62%
Jul-14-17 04:15PM  Calumet Specialty Products Partners, L.P. To Release Second Quarter 2017 Results on August 4th PR Newswire
Jul-12-17 08:36AM  Calumet Specialty Products Partners LP breached its 50 day moving average in a Bullish Manner : CLMT-US : July 12, 2017 Capital Cube
Jul-07-17 09:09AM  These MLPs Took June in Stride Market Realist
Jun-26-17 05:44PM  Calumet Specialty Products Partners LP Value Analysis (NASDAQ:CLMT) : June 26, 2017 Capital Cube
Jun-23-17 08:19AM  Calumet Specialty Products Partners LP breached its 50 day moving average in a Bullish Manner : CLMT-US : June 23, 2017 Capital Cube
Jun-20-17 12:28PM  Here's Why CVR Refining's Management Refuses to Pay Investors a Dividend Right Now Motley Fool
Jun-07-17 09:07AM  A Look at the Top-Performing MLPs in May 2017 Market Realist
Jun-02-17 08:45AM  Calumet Specialty Products Partners LP breached its 50 day moving average in a Bullish Manner : CLMT-US : June 2, 2017 Capital Cube
Jun-01-17 04:15PM  Calumet Specialty Products Partners, L.P. To Attend Upcoming Bank Of America Merrill Lynch 2017 Energy Credit Conference PR Newswire
May-26-17 09:03AM  Increased Earnings Estimates Seen for Calumet Specialty Products (CLMT): Can It Move Higher? Zacks
May-16-17 07:39AM  Top Movers in Energy for May 812, 2017 Market Realist
May-12-17 11:14AM  Calumet Specialty Products Partners LP :CLMT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 09:21PM  Edited Transcript of CLMT earnings conference call or presentation 4-May-17 5:00pm GMT Thomson Reuters StreetEvents
May-09-17 09:00AM  Calumet Specialty Products Partners, L.P. Announces Launch of Uninhibited Transformer Oil PR Newswire +6.33%
May-08-17 07:38AM  Integrated Energy and Refiners: How Returns Impact Volatilities Market Realist
07:38AM  Option Traders, Watch These Integrated Energy and Refiner Stocks Market Realist
07:37AM  Calumet Specialty Products Partners' Improved Operations Help Boost Earnings Motley Fool
May-04-17 02:55PM  Shares of Calumet Specialty Products Partners Spike 11% on Earnings Announcement Motley Fool +11.43%
09:25AM  Investor Network: Calumet Specialty Products Partners, L.P. to Host Earnings Call Accesswire
08:00AM  Calumet Specialty Products Partners, L.P. Reports First Quarter 2017 Results PR Newswire
May-01-17 04:22PM  Calumet Specialty Products Partners, L.P. Announces Launch of Group III Synthetic Base Oil PR Newswire
Apr-28-17 01:06PM  How CVR Refinings Refining Margin Improved in 1Q17 Market Realist
11:15AM  CVR Refinings 1Q17 Results Driven by Throughput Volumes, Spreads Market Realist
Apr-21-17 11:31AM  7 Things You Didn't Know About Calumet Specialty Products Partners LP Motley Fool
09:00AM  Calumet Specialty Products Partners, L.P. To Release First Quarter 2017 Results on May 4th PR Newswire
Apr-11-17 10:36AM  Where Calumet Specialty Products May Be Headed Market Realist
09:06AM  Calumets Institutional Ownership: Key Indications Market Realist
07:37AM  Calumets Leverage Moves in Right DirectionBut Remains High Market Realist
Apr-10-17 05:35PM  Will Calumet Generate Positive Distributable Cash Flow in 2017? Market Realist
04:05PM  Inside Calumet Segmental Performances Market Realist
02:08PM  Calumet Stock: Any Sign of Recovery? Market Realist
Apr-04-17 11:05AM  Integrated Energy and Refiners: Options for Option Traders Market Realist
11:05AM  Integrated Energy and Refiners: Options for Option Traders
11:05AM  Integrated Energy and Refiners: Inside the Returns and Volatilities Market Realist
11:05AM  Integrated Energy and Refiners: Inside the Returns and Volatilities
Mar-31-17 04:26PM  CALUMET SPECIALTY PRODUCTS PARTNERS, L.P. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation F
04:15PM  Calumet Specialty Products Partners, L.P. Announces Change of Board of Directors' Composition PR Newswire
12:36PM  Integrated Energy and Refiner Stocks Returns and Volatilities Market Realist
12:36PM  Integrated Energy and Refiner Stocks Returns and Volatilities
10:53AM  Integrated Energy and Refiners: Who Tops in Implied Volatility? Market Realist
10:53AM  Integrated Energy and Refiners: Who Tops in Implied Volatility?
Mar-17-17 11:10AM  Integrated Energy and Refiner Stocks Implied Volatilities Market Realist
11:10AM  Integrated Energy and Refiner Stocks Implied Volatilities
Mar-10-17 04:05PM  Implied Volatilities of Integrated Energy and Refiners Market Realist
04:05PM  Implied Volatilities of Integrated Energy and Refiners
02:14PM  Integrated Energy and Refiners: Who Leads in Implied Volatility? Market Realist
02:14PM  Integrated Energy and Refiners: Who Leads in Implied Volatility?
01:04PM  CALUMET SPECIALTY PRODUCTS PARTNERS, L.P. Financials
Mar-09-17 12:16PM  Calumet Specialty Products Partners LP :CLMT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 Capital Cube
Calumet Specialty Products Partners, L.P. produces and sells specialty hydrocarbon products in North America. It operates in three segments: Specialty Products, Fuel Products, and Oilfield Services. The Specialty Products segment offers various lubricating oils, white mineral oils, petrolatums, solvents, waxes, synthetic lubricants, and other products which are used primarily as raw material components for basic automotive, industrial, and consumer goods. The Fuel Products segment provides fuel and fuel-related products, including gasoline, diesel, jet fuel, asphalt, and heavy fuel oils, as well as resells purchased crude oil to third party customers. The Oilfield Services segment manufactures and markets drilling fluids, completion fluids, and solids control services to the oil and gas exploration industry. Calumet GP, LLC serves as the general partner for Calumet Specialty Products Partners, L.P. The company was founded in 1916 and is headquartered in Indianapolis, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Griffin David WestEVP and CFOAug 04Buy5.354532,42454,905Aug 07 04:57 PM
Griffin David WestEVP and CFOAug 03Buy5.1510051554,452Aug 07 04:57 PM
Griffin David WestEVP and CFOAug 02Buy5.173,00015,51254,352Aug 02 05:10 PM
Griffin David WestEVP and CFOAug 01Buy5.202,10010,92051,352Aug 02 05:10 PM
Griffin David WestEVP and CFOJul 31Buy5.213,00015,63049,252Aug 02 05:10 PM
Griffin David WestEVP and CFOJul 28Buy5.2010052046,252Jul 28 05:26 PM
Griffin David WestEVP and CFOJul 27Buy5.143,00015,42546,152Jul 28 05:26 PM
Griffin David WestEVP and CFOJul 26Buy5.343,00016,02243,152Jul 28 05:26 PM
Griffin David WestEVP and CFOJul 25Buy5.2010052040,152Jul 25 05:55 PM
Griffin David WestEVP and CFOJul 24Buy5.141,8839,68740,052Jul 25 05:55 PM
Griffin David WestEVP and CFOJul 21Buy4.881,8008,78038,169Jul 25 05:55 PM
Griffin David WestEVP and CFOJul 20Buy4.703001,41036,369Jul 20 05:45 PM
Griffin David WestEVP and CFOJul 19Buy4.453001,33536,069Jul 20 05:45 PM
Griffin David WestEVP and CFOJul 18Buy4.2420084835,769Jul 20 05:45 PM
Griffin David WestEVP and CFOJul 17Buy4.123691,52135,569Jul 17 06:05 PM
Griffin David WestEVP and CFOJul 14Buy4.133,00012,37735,200Jul 17 06:05 PM
Griffin David WestEVP and CFOJul 13Buy4.163,00012,47332,200Jul 17 06:05 PM
Griffin David WestEVP and CFOJul 12Buy4.193,00012,55729,200Jul 12 06:30 PM
Griffin David WestEVP and CFOJul 11Buy4.153001,24526,200Jul 12 06:30 PM
Griffin David WestEVP and CFOJul 10Buy4.033001,21025,900Jul 12 06:30 PM
Griffin David WestEVP and CFOJul 07Buy4.103,00012,29325,600Jul 07 05:24 PM
Griffin David WestEVP and CFOJul 06Buy4.173,00012,51022,600Jul 07 05:24 PM
Griffin David WestEVP and CFOJul 05Buy4.173,00012,52319,600Jul 07 05:24 PM
Griffin David WestEVP and CFOJul 03Buy4.223,00012,66816,600Jul 05 05:55 PM
Griffin David WestEVP and CFOJun 30Buy4.193,00012,57513,600Jul 05 05:55 PM
Griffin David WestEVP and CFOJun 29Buy4.163,00012,48010,600Jun 30 04:38 PM
Griffin David WestEVP and CFOJun 28Buy4.141,6006,6277,600Jun 30 04:38 PM
Griffin David WestEVP and CFOJun 27Buy4.103,00012,2956,000Jun 28 04:37 PM
Griffin David WestEVP and CFOJun 26Buy4.073,00012,2003,000Jun 28 04:37 PM
Mawer Stephen PDirectorMar 07Buy3.903,60014,02229,037Mar 08 08:08 AM
Fleming Bruce AEVP - Strategy & GrowthMar 01Option Exercise0.0035,7600178,799Mar 03 05:17 PM
Schumacher Amy MDirectorMar 01Option Exercise0.009,447019,945Mar 03 05:52 PM
Sajkowski Daniel JDirectorMar 01Option Exercise0.009,447014,545Mar 03 05:50 PM
Mawer Stephen PDirectorMar 01Option Exercise0.007,937025,437Mar 03 05:49 PM
Funk Robert EDirectorMar 01Option Exercise0.0013,805064,141Mar 03 05:41 PM
Morris George C IIIDirectorMar 01Option Exercise0.0010,359093,892Mar 03 05:42 PM
Fehsenfeld Fred M JrChairman of the BoardMar 01Option Exercise0.0013,7100452,408Mar 03 05:38 PM
Carter James SDirectorMar 01Option Exercise0.0013,9610107,402Mar 03 05:37 PM
William A AndersonEVP - SalesMar 01Option Exercise0.005,400065,400Mar 03 05:27 PM
Go TimothyChief Executive OfficerMar 01Option Exercise0.007,5960123,108Mar 03 05:24 PM
Murray Richard Patrick IIEVP and CFOMar 01Option Exercise0.009,856098,691Mar 03 05:21 PM
Grube Ferdinand WilliamExecutive Vice Chairman of BODMar 01Option Exercise0.008,1000189,828Mar 03 05:20 PM
Go TimothyChief Executive OfficerFeb 28Buy3.9420,00078,800111,682Mar 02 07:19 AM
Go TimothyChief Executive OfficerNov 25Buy4.257693,26891,682Nov 28 05:37 PM
Go TimothyChief Executive OfficerNov 18Buy4.655,00023,25090,913Nov 21 05:05 PM
Go TimothyChief Executive OfficerNov 17Buy4.855,00024,24585,913Nov 21 05:05 PM
Go TimothyChief Executive OfficerNov 16Buy4.808574,11480,913Nov 17 07:05 PM
Fleming Bruce AEVP - Strategy & GrowthNov 15Buy4.3340173143,039Nov 16 08:35 AM
Go TimothyChief Executive OfficerNov 15Buy4.4510044580,056Nov 17 07:05 PM
William A AndersonEVP - SalesNov 14Buy4.1020,10882,44360,000Nov 15 04:27 PM
Go TimothyChief Executive OfficerNov 11Buy4.205,00020,99079,956Nov 14 08:42 AM
Go TimothyChief Executive OfficerNov 10Buy4.305,00021,49374,956Nov 14 08:42 AM
Mawer Stephen PDirectorNov 09Buy3.654,00014,58017,500Nov 09 05:32 PM
Fleming Bruce AEVP - Strategy & GrowthNov 08Buy3.3957,999196,617142,999Nov 10 05:39 PM
Go TimothyChief Executive OfficerNov 08Buy3.376,60422,23869,956Nov 14 08:42 AM
William A AndersonEVP - SalesNov 07Buy3.403,67012,4783,550Nov 09 06:38 PM
William A AndersonEVP - SalesNov 07Buy3.4014,50049,30039,892Nov 09 06:38 PM
NLNK NewLink Genetics Corporation daily Stock Chart
NLNK [NASD]
NewLink Genetics Corporation
Index- P/E- EPS (ttm)-2.29 Insider Own21.90% Shs Outstand37.91M Perf Week-6.23%
Market Cap382.13M Forward P/E- EPS next Y-2.44 Insider Trans10.38% Shs Float27.88M Perf Month-6.75%
Income-66.70M PEG- EPS next Q-0.74 Inst Own49.30% Short Float29.59% Perf Quarter37.70%
Sales41.20M P/S9.28 EPS this Y-108.00% Inst Trans6.51% Short Ratio3.11 Perf Half Y-45.78%
Book/sh3.51 P/B2.87 EPS next Y12.10% ROA-41.20% Target Price24.40 Perf Year-31.94%
Cash/sh- P/C- EPS next 5Y16.80% ROE-55.00% 52W Range5.90 - 25.17 Perf YTD-1.95%
Dividend- P/FCF- EPS past 5Y0.30% ROI-65.70% 52W High-59.95% Beta1.20
Dividend %- Quick Ratio5.00 Sales past 5Y80.40% Gross Margin- 52W Low70.85% ATR0.92
Employees122 Current Ratio5.00 Sales Q/Q420.00% Oper. Margin- RSI (14)49.32 Volatility5.48% 9.32%
OptionableYes Debt/Eq0.00 EPS Q/Q48.90% Profit Margin- Rel Volume0.36 Prev Close10.29
ShortableYes LT Debt/Eq0.00 EarningsOct 31 BMO Payout- Avg Volume2.66M Price10.08
Recom1.40 SMA20-4.23% SMA502.88% SMA200-19.91% Volume956,017 Change-2.04%
Oct-13-17Initiated BofA/Merrill Buy $22
Sep-11-17Reiterated Stifel Buy $14 → $29
Sep-08-17Upgrade Robert W. Baird Neutral → Outperform $8 → $22
Sep-08-17Upgrade Jefferies Hold → Buy
Jun-08-17Downgrade Robert W. Baird Outperform → Neutral $25 → $8
Mar-30-17Upgrade SunTrust Hold → Buy
May-11-16Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
May-10-16Reiterated Stifel Buy $63 → $23
May-10-16Reiterated Mizuho Buy $52 → $20
Mar-23-16Initiated Robert W. Baird Outperform $27
Mar-01-16Reiterated Mizuho Buy $62 → $52
Jul-15-15Reiterated Mizuho Buy $50 → $62
Jul-15-15Reiterated Cantor Fitzgerald Buy $44 → $62
May-06-15Reiterated Stifel Buy $59 → $63
Nov-07-14Reiterated Stifel Buy $51 → $55
Sep-12-14Initiated Mizuho Buy $50
Mar-31-14Reiterated MLV & Co Buy $29 → $45
Mar-03-14Downgrade Robert W. Baird Outperform → Neutral
Jan-22-14Reiterated Stifel Buy $31 → $53
Dec-13-13Reiterated Stifel Buy $28 → $31
Oct-20-17 08:00AM  NewLink Genetics to Host Its Third Quarter 2017 Financial Results Conference Call on November 2, 2017 GlobeNewswire
Oct-16-17 09:57AM  ETFs with exposure to NewLink Genetics Corp. : October 16, 2017 Capital Cube
Oct-13-17 09:58AM  Bank Of America Sees NewLink Genetics As 'Undervalued' Benzinga
Oct-09-17 11:34AM  The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September Motley Fool
Oct-04-17 12:42PM  Here's Why NewLink Genetics Corp. Stock Is Surging Again Today Motley Fool +8.80%
08:36AM  Before You Invest In NewLink Genetics Corporation (NLNK), Consider This Factor Simply Wall St.
08:00AM  Today's Research Reports on Trending Tickers: Anthera Pharmaceuticals and NewLink Genetics ACCESSWIRE
Oct-03-17 08:54PM  NewLink Genetics Prices Public Offering of Common Stock GlobeNewswire +5.00%
06:15PM  Edited Transcript of NLNK earnings conference call or presentation 28-Jul-17 12:30pm GMT Thomson Reuters StreetEvents
04:07PM  NewLink Genetics Announces Proposed Public Offering of Common Stock Business Wire
Oct-02-17 10:59AM  ETFs with exposure to NewLink Genetics Corp. : October 2, 2017 Capital Cube
Sep-25-17 06:00AM  NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer GlobeNewswire -8.19%
Sep-21-17 07:47AM  3 Small-Cap Biotech Stocks to Buy This Fall Motley Fool
Sep-19-17 06:12PM  ETFs with exposure to NewLink Genetics Corp. : September 19, 2017 Capital Cube
Sep-18-17 12:57PM  NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-11-17 03:15PM  Analyst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside Benzinga -5.83%
08:42AM  NewLink Genetics (NLNK) Jumps: Stock Rises 29.9% Zacks
Sep-09-17 10:02AM  3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? Motley Fool
Sep-08-17 04:46PM  Why NewLink Genetics, Zumiez, and Everest Re Group Jumped Today Motley Fool +29.93%
01:12PM  Why NewLink Genetics Is Soaring 37.5% Higher Today Motley Fool
10:39AM  Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers TheStreet.com
09:50AM  Why NewLink Genetics Corporation (NLNK) Could Be A Buy Simply Wall St.
08:40AM  Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock Zacks
08:10AM  Today's Research Reports on Trending Tickers: AstraZeneca and NewLink Genetics ACCESSWIRE
Sep-07-17 06:10PM  3 Stocks Soaring Today GuruFocus.com +74.58%
01:01PM  Here's Why NewLink Genetics Is Vaulting 45% Higher Today Motley Fool
07:00AM  Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma Business Wire
Aug-29-17 07:00AM  NewLink Genetics to Participate in Upcoming Investor Conferences GlobeNewswire
Jul-28-17 11:35PM  NewLink reports 2Q loss Associated Press +10.00%
09:12AM  Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent TheStreet.com
08:00AM  NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program GlobeNewswire
06:15AM  Investor Network: Newlink Genetics Corporation to Host Earnings Call ACCESSWIRE
Jul-27-17 07:00AM  NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802 GlobeNewswire
Jul-12-17 02:48PM  ETFs with exposure to NewLink Genetics Corp. : July 12, 2017 Capital Cube
Jul-10-17 07:00AM  NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs GlobeNewswire
Jul-07-17 07:00AM  NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017 GlobeNewswire
Jun-23-17 07:00AM  Positive Phase 1b Data for NewLink Genetics IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Presented at the European Hematologic Association (EHA) Congress in Madrid, Spain GlobeNewswire
Jun-21-17 03:43PM  These 3 Biotechs Have Been Crushed; Is It Time to Bargain Shop? Motley Fool +9.04%
Jun-19-17 08:00AM  A Surprising Disappointment Derails NewLink Genetics -- What's Next? Motley Fool
Jun-13-17 08:49AM  Are Options Traders Betting on a Big Move in NewLink (NLNK) Stock? Zacks
Jun-09-17 04:27PM  Roche-NewLink Drug Move Shouldn't Impact Incyte, Says Analyst Investor's Business Daily
Jun-08-17 05:03PM  Why Sina, Eldorado Gold, and NewLink Genetics Slumped Today Motley Fool -41.24%
04:20PM  Stocks Pull Off Narrow Win, But These Four Soared To New Highs Investor's Business Daily
02:28PM  Why Is NewLink Genetics Losing One-Third of Its Value Today? Motley Fool
09:20AM  NewLink Genetics Sinks After Regaining Licensing Rights for Its Cancer Treatment 24/7 Wall St.
09:20AM  Biotech Movers: NewLink, Inovio, Juno TheStreet.com
08:56AM  NewLink Genetics' stock plunges as Genentech plans to returns rights cancer treatment candidate MarketWatch
07:00AM  NewLink Genetics to Regain Rights to GDC-0919 GlobeNewswire
Jun-05-17 04:50PM  Why Herbalife, JinkoSolar, and NewLink Genetics Slumped Today Motley Fool -12.39%
09:25AM  Biotech Movers: Loxo, NewLink, BioCryst TheStreet.com
09:00AM  NewLink Genetics Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival (rPFS) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase 2 Trial GlobeNewswire
Jun-02-17 04:01PM  Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer GlobeNewswire
06:56AM  Cancer drug prices could double or triple thanks to this popular but unproven drug trend MarketWatch
May-30-17 09:35AM  Update in Lawsuit for Investors in NewLink Genetics Corp (NASDAQ: NLNK) Shares Announced by Shareholders Foundation Accesswire -9.21%
May-18-17 05:32PM  Incyte Teams Up With Dow's Merck To Trounce Roche In Cancer Investor's Business Daily -9.07%
03:33PM  Biotech Stocks: Is ASCO Much Ado About Nothing? Barrons.com
06:00AM  Data from Clinical Study of NewLink Genetics IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress GlobeNewswire
May-17-17 05:05PM  Data from Clinical Studies of NewLink Genetics Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017 GlobeNewswire
May-15-17 09:00PM  Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation - NLNK Business Wire
May-11-17 05:14PM  ETFs with exposure to NewLink Genetics Corp. : May 11, 2017 Capital Cube
May-09-17 10:52AM  NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 Capital Cube
May-08-17 07:00AM  NewLink Genetics to Participate in Upcoming Investor Conferences GlobeNewswire
May-05-17 08:22AM  3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month Motley Fool
May-04-17 09:21AM  NewLink reports 1Q loss Associated Press
08:00AM  NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance GlobeNewswire
07:20AM  Investor Network: Newlink Genetics Corporation to Host Earnings Call Accesswire
May-03-17 07:16PM  Lifshitz & Miller LLP Announces Investigation of Bingo Nation Inc., BofI Holding, Inc., Corbus Pharmaceuticals Holdings, Inc., Lion Biotechnologies, Inc., NewLink Genetics Corporation, Power Solutions International, Inc., Walter Investment Management Corp. and XBIOTECH INC. PR Newswire
Apr-25-17 12:34AM  Vaunted Ebola Vaccine Faces Questions The Wall Street Journal
Apr-24-17 06:23PM  Vaunted Ebola Vaccine Faces Questions The Wall Street Journal
Apr-21-17 03:41PM  NewLink Genetics Corp. Value Analysis (NASDAQ:NLNK) : April 21, 2017 Capital Cube
12:02PM  Should Gilead Sciences Acquire NewLink Genetics? Motley Fool
07:00AM  NewLink Genetics Announces Presentation of Two Abstracts at ASCO GlobeNewswire
Apr-20-17 08:20AM  NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : April 20, 2017 Capital Cube
Apr-13-17 12:01PM  Morgan Stanley Ups Incyte Target to $150 Barrons.com
10:41AM  The IDO-Inhibitor Race Is On to Improve Cancer Treatment Motley Fool
08:00AM  NewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017 GlobeNewswire
Apr-07-17 05:08PM  ETFs with exposure to NewLink Genetics Corp. : April 7, 2017 Capital Cube -7.70%
10:17AM  NewLink Genetics Corp. breached its 50 day moving average in a Bearish Manner : NLNK-US : April 7, 2017 Capital Cube
Apr-05-17 04:56PM  Why NewLink Genetics, Harmonic, and Innophos Holdings Slumped Today Motley Fool -14.00%
Apr-04-17 05:07PM  Why NewLink Genetics Shares Fell 10.3% Today Motley Fool -9.96%
04:02PM  NEWLINK GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm Business Wire
09:48AM  NewLink Genetics Corp. stock drops 28% on mid-stage results for melanoma drug MarketWatch
08:30AM  Interim Phase 2 Data Demonstrate Robust Response Rate with Indoximod in Combination with Keytruda® (pembrolizumab) for Patients with Advanced Melanoma at AACR Plenary GlobeNewswire
Mar-31-17 09:30AM  TrovaGene and NewLink Genetics Find Investors Optimistic About Products Accesswire
Mar-30-17 04:07PM  NewLink Genetics' shares surge after upgrade, seen as takeover target CNBC +5.62%
10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Zacks
07:08AM  NewLink Genetics upgraded by SunTrust
Mar-20-17 08:34AM  NEWLINK GENETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Di
Mar-17-17 08:15AM  Blog Coverage PTC Therapeutics Acquires Rights for Duchenne Muscular Dystrophy Drug from Marathon for $140 Million Upfront Accesswire
Mar-10-17 01:04PM  NEWLINK GENETICS CORP Financials
Mar-07-17 01:23PM  NewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube -5.21%
Mar-06-17 02:16PM  NEWLINK GENETICS CORP Files SEC form 10-K, Annual Report
07:04AM  Four Companies Breaking Out Right Now With Record Growth
Mar-01-17 05:30PM  NEWLINK GENETICS CORP Files SEC form 8-K, Other Events +6.81%
05:05PM  NewLink Genetics Announces Presentation of Two Abstracts at AACR GlobeNewswire
Feb-28-17 08:45AM  NewLink reports 4Q loss
08:35AM  NEWLINK GENETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
08:00AM  NewLink Genetics Provides Operational & Clinical Update, Reports Fourth Quarter, Year-End 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 NewLink Genetics Corp Earnings Release - Before Market Open
Feb-21-17 10:02AM  NewLink Genetics (NLNK): Moving Average Crossover Alert
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The company's HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses. The company has license and collaboration agreements with Genentech, Inc. and Merck, Sharpe and Dohme Corp. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stine Seed Farm, Inc.10% OwnerOct 06Buy10.25780,4877,999,9927,857,732Oct 06 05:00 PM
Langren Carl W.Principal Accounting OfficerDec 14Sale10.853,94342,78210,691Dec 16 05:53 PM
ENDP Endo International plc daily Stock Chart
ENDP [NASD]
Endo International plc
Index- P/E- EPS (ttm)-19.68 Insider Own0.50% Shs Outstand225.20M Perf Week-5.51%
Market Cap1.74B Forward P/E2.55 EPS next Y3.03 Insider Trans3.30% Shs Float222.01M Perf Month-12.27%
Income-4386.30M PEG- EPS next Q0.67 Inst Own89.20% Short Float9.60% Perf Quarter-33.85%
Sales4.04B P/S0.43 EPS this Y-850.90% Inst Trans-4.57% Short Ratio3.44 Perf Half Y-29.17%
Book/sh3.63 P/B2.13 EPS next Y-14.10% ROA-35.70% Target Price11.94 Perf Year-62.40%
Cash/sh- P/C- EPS next 5Y- ROE-174.50% 52W Range7.40 - 21.87 Perf YTD-53.13%
Dividend- P/FCF6.40 EPS past 5Y-61.60% ROI-25.30% 52W High-64.70% Beta0.59
Dividend %- Quick Ratio0.80 Sales past 5Y9.70% Gross Margin37.60% 52W Low4.32% ATR0.46
Employees4894 Current Ratio1.00 Sales Q/Q-4.90% Oper. Margin-99.90% RSI (14)41.24 Volatility5.70% 5.63%
OptionableYes Debt/Eq10.24 EPS Q/Q-278.30% Profit Margin- Rel Volume0.50 Prev Close7.88
ShortableYes LT Debt/Eq10.20 EarningsNov 09 AMC Payout- Avg Volume6.20M Price7.72
Recom2.80 SMA20-8.37% SMA50-9.32% SMA200-29.78% Volume3,101,745 Change-2.03%
Sep-28-17Initiated Goldman Sell $7
Aug-09-17Reiterated RBC Capital Mkts Sector Perform $15 → $9
Jun-16-17Initiated Cantor Fitzgerald Neutral $12
Jun-09-17Downgrade Stifel Buy → Hold $22 → $15
May-25-17Reiterated Mizuho Buy $18 → $19
Feb-22-17Initiated Canaccord Genuity Hold $14
Jan-31-17Reiterated Mizuho Buy $25 → $15
Jan-20-17Downgrade JP Morgan Overweight → Neutral
Jan-05-17Downgrade Citigroup Buy → Neutral
Dec-07-16Resumed Oppenheimer Perform
Nov-11-16Reiterated Mizuho Buy $29 → $25
Nov-10-16Upgrade Susquehanna Neutral → Positive
Nov-09-16Reiterated RBC Capital Mkts Outperform $26 → $21
Sep-29-16Upgrade Northland Capital Market Perform → Outperform
Aug-12-16Upgrade Mizuho Neutral → Buy $16 → $29
Jun-13-16Upgrade Mizuho Underperform → Neutral $13 → $16
Jun-06-16Initiated Goldman Neutral $20
May-18-16Reiterated Stifel Buy $75 → $25
May-09-16Reiterated Deutsche Bank Buy $61 → $31
May-06-16Reiterated Stifel Buy $90 → $75
Oct-18-17 08:04AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
Oct-17-17 12:14PM  Amneal, Impax combine to tackle generic drug pricing pressure Reuters
11:57AM  DEADLINE TODAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm GlobeNewswire
10:17AM  ENDP DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017 ACCESSWIRE
Oct-16-17 02:58PM  DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm ACCESSWIRE -6.73%
02:30PM  ENDP FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline: October 17, 2017 ACCESSWIRE
10:57AM  DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP ACCESSWIRE
10:06AM  Endo International Plc Value Analysis (NASDAQ:ENDP) : October 16, 2017 Capital Cube
Oct-13-17 08:35AM  Endo International Plc breached its 50 day moving average in a Bearish Manner : ENDP-US : October 13, 2017 Capital Cube
Oct-12-17 09:56PM  Is Endo International plc (ENDP) Undervalued? Simply Wall St. -8.24%
Oct-11-17 04:42PM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm ACCESSWIRE
12:13PM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (ENDP) GlobeNewswire
Oct-10-17 02:53PM  ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Reminds Investors with Losses to Contact the Firm GlobeNewswire
10:30AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP ACCESSWIRE
10:05AM  Investor ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) - Lead Plaintiff Deadline: October 17, 2017 ACCESSWIRE
Oct-09-17 01:12PM  EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:22AM  ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017 GlobeNewswire
08:04AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
07:30AM  Endo to Announce Third-Quarter 2017 Financial Results CNW Group
Oct-05-17 06:27PM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
05:51PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Endo International plc ENDP GlobeNewswire
11:31AM  Omeros shares surge 10% after settlement with Endo delays generic to 2032 MarketWatch
Oct-04-17 02:15PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
11:32AM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP GlobeNewswire
Oct-03-17 03:47PM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
10:43AM  The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017 (ENDP) ACCESSWIRE
08:15AM  Endo International Plc breached its 50 day moving average in a Bullish Manner : ENDP-US : October 3, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Endo International ACCESSWIRE
Oct-02-17 04:04PM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +6.13%
10:34AM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP ACCESSWIRE
Sep-29-17 11:33PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +5.09%
10:48AM  Debt Worries Outweigh Specialty Pharma Pipeline Potential Barrons.com
10:35AM  ENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017 ACCESSWIRE
Sep-28-17 03:55PM  Is It The Right Time To Buy Endo International plc (ENDP)? Simply Wall St. -9.85%
01:00PM  IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm GlobeNewswire
11:45AM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP ACCESSWIRE
10:17AM  Investor ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline: October 17, 2017 ACCESSWIRE
08:45AM  Morning Movers: Endo Slumps, Hain Jumps, Philip Morris Rises Barrons.com
Sep-27-17 08:04AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit +8.00%
Sep-26-17 06:30AM  Four-Time PGA TOUR Winner Tim Herron Teams Up with Endo Pharmaceuticals to Encourage Adults to Get the Facts on Hand PR Newswire
Sep-25-17 01:10PM  IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm GlobeNewswire
11:18AM  The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017 Business Wire
10:25AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) - Lead Plaintiff Deadline: October 17, 2017 ACCESSWIRE
09:55AM  Should Value Investors Consider Endo International (ENDP) Stock? Zacks
Sep-20-17 01:01PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm PR Newswire
12:10PM  ENDP INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017 Business Wire
08:02AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
Sep-19-17 12:22PM  State attorneys general subpoena opioid makers and dealer... CNBC Videos
11:51AM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm PR Newswire
08:56AM  Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock? Zacks
08:03AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
Sep-18-17 12:37PM  Why Allergan Could Be A $300 Stock Barrons.com
11:48AM  EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 Business Wire
10:33AM  Valeant Pharmaceuticals: Is A New Drug Approval On The Horizon? Barrons.com
09:53AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm Business Wire
09:07AM  Regeneron Is Focused on Advancing Development of Fasinumab for Chronic Pain Market Realist
08:04AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
Sep-15-17 06:16PM  ENDO LOSS NOTICE: Rosen Law Firm Reminds Endo International plc Investors of Important Deadline in Class Action ENDP Business Wire
04:09PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm Business Wire
01:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Endo International plc - ENDP ACCESSWIRE
01:24PM  SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Endo International plc Business Wire
12:19PM  The Klein Law Firm Notifies Investors of Commencement of a Class Action Filed on Behalf of Endo International plc Shareholders and a Lead Plaintiff Deadline of October 17, 2017 Business Wire
Sep-14-17 11:23AM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm Business Wire -7.11%
10:24AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline: October 17, 2017 ACCESSWIRE
08:05AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
Sep-13-17 06:05PM  ETFs with exposure to Endo International Plc : September 13, 2017 Capital Cube
01:57PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Endo International plc and Encourages Investors with Losses to Contact the Firm Business Wire
12:50PM  ENDP EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017 Business Wire
Sep-12-17 12:53PM  INVESTOR ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Endo International plc Business Wire
11:54AM  ENDP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Endo International plc and a Lead Plaintiff Deadline of October 17, 2017 GlobeNewswire
08:07AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
08:00AM  Today's Research Reports on Trending Tickers: Endo International and Valeant Pharmaceuticals ACCESSWIRE
Sep-11-17 12:42PM  Endo International Plc :ENDP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube +6.42%
12:15PM  INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 -- ENDP GlobeNewswire
10:22AM  New Strong Sell Stocks for September 11th Zacks
10:10AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Endo International plc (ENDP) & Lead Plaintiff Deadline: October 17, 2017 PR Newswire
Sep-08-17 06:00PM  EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Endo International plc ENDP Business Wire
10:23AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
Sep-05-17 04:51PM  Why Mallinckrodt Got Crushed Barrons.com
12:21PM  The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Endo International plc Business Wire
Aug-31-17 12:28PM  The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Endo International plc Business Wire
10:30AM  New Strong Sell Stocks for August 31st Zacks
Aug-30-17 04:30PM  IMPORTANT ENDO INTERNATIONAL PLC INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Endo International plc GlobeNewswire
Aug-28-17 07:30AM  Endo Begins Shipment of Generic Sabril® (vigabatrin) for Oral Solution PR Newswire
Aug-25-17 06:06PM  Will Endo (ENDP) Continue to Disappoint Investors in 2017? Zacks
Aug-22-17 08:03AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
07:30AM  Endo to Participate at Morgan Stanley Global Healthcare Conference PR Newswire
07:30AM  Endo to Participate at Morgan Stanley Global Healthcare Conference CNW Group
Aug-18-17 03:40PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Endo International plc and Set a Lead Plaintiff Deadline of October 17, 2017 Business Wire
Aug-17-17 08:48AM  Endo International (ENDP) Jumps: Stock Rises 6.9% Zacks
Aug-13-17 12:46PM  Edited Transcript of ENDP earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 10:20AM  BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls Zacks
08:01AM  See what the IHS Markit Score report has to say about Endo International PLC. Markit
Aug-08-17 10:27PM  Endo reports 2Q loss Associated Press -12.14%
02:02PM  Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered Zacks
01:59PM  As Drug Overdoses Hit Record High, Trump Offers Little on Opioid Policy Fortune
10:15AM  Endo's stock tumbles to 14 1/2-year low after drug maker swings to large loss MarketWatch
09:38AM  Endo's U.S. generics business beats estimates Reuters
07:18AM  Endo (ENDP) Q2 Earnings Beat Estimates, 2017 Guidance Cut Zacks
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating Peyronie's and Dupuytren's contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of advanced prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, women's health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman BlaiseEVP, Chief Financial OfficerAug 15Buy7.896,50051,28513,729Aug 15 02:15 PM
Maletta Matthew JosephEVP, Chief Legal OfficerAug 15Buy8.023,00024,0606,984Aug 15 02:55 PM
Campanelli PaulPresident, CEOAug 14Buy7.716,50050,115213,620Aug 15 02:31 PM
Coughlin Terrance JEVP, Chief Operating OfficerAug 10Buy7.7020,000154,000140,582Aug 11 09:04 AM
Campanelli PaulPresident, CEOMar 16Buy10.722,30024,656207,120Mar 16 05:54 PM
Hutson Nancy JDirectorMar 09Sale10.825,32557,61731,252Mar 10 10:24 AM
KIMMEL ROGER HDirectorNov 15Sale17.387,000121,632188,000Nov 16 02:00 PM
KIMMEL ROGER HDirectorNov 15Sale17.387,000121,63268,362Nov 16 02:00 PM
SPSC SPS Commerce, Inc. daily Stock Chart
SPSC [NASD]
SPS Commerce, Inc.
Index- P/E116.13 EPS (ttm)0.52 Insider Own0.10% Shs Outstand17.20M Perf Week3.07%
Market Cap1.05B Forward P/E57.79 EPS next Y1.05 Insider Trans-5.43% Shs Float17.14M Perf Month8.66%
Income9.10M PEG5.16 EPS next Q0.20 Inst Own- Short Float2.90% Perf Quarter3.61%
Sales206.60M P/S5.07 EPS this Y21.60% Inst Trans-0.24% Short Ratio4.95 Perf Half Y6.46%
Book/sh16.22 P/B3.75 EPS next Y20.21% ROA2.90% Target Price69.11 Perf Year-11.28%
Cash/sh9.22 P/C6.60 EPS next 5Y22.50% ROE3.50% 52W Range48.11 - 73.16 Perf YTD-12.93%
Dividend- P/FCF53.39 EPS past 5Y-21.00% ROI1.80% 52W High-16.83% Beta1.11
Dividend %- Quick Ratio5.50 Sales past 5Y27.20% Gross Margin66.60% 52W Low26.48% ATR1.25
Employees1217 Current Ratio5.50 Sales Q/Q14.60% Oper. Margin5.60% RSI (14)64.42 Volatility2.19% 2.22%
OptionableYes Debt/Eq0.00 EPS Q/Q410.80% Profit Margin4.40% Rel Volume1.43 Prev Close59.46
ShortableYes LT Debt/Eq0.00 EarningsOct 26 AMC Payout0.00% Avg Volume100.27K Price60.85
Recom2.30 SMA205.63% SMA504.07% SMA2001.93% Volume143,263 Change2.34%
Jul-21-17Initiated Oppenheimer Outperform $74
Apr-28-17Reiterated Needham Buy $70 → $64
Feb-08-17Downgrade Pacific Crest Overweight → Sector Weight
Feb-08-17Downgrade Canaccord Genuity Buy → Hold $82 → $65
Dec-06-16Initiated The Benchmark Company Buy $84
Sep-30-16Initiated Pacific Crest Overweight $85
Sep-27-16Initiated First Analysis Sec Overweight $86
Sep-26-16Reiterated Needham Buy $70 → $83
Jul-27-16Reiterated Needham Buy $60 → $70
Jul-24-15Reiterated Stifel Buy $80 → $85
Jul-24-15Reiterated Northland Capital Outperform $82 → $87
Jul-24-15Reiterated Canaccord Genuity Buy $80 → $83
Jul-23-15Reiterated Needham Buy $72 → $86
Jun-28-13Reiterated Stifel Buy $46 → $60
Apr-26-13Reiterated Northland Capital Outperform $43 → $48
Apr-02-13Initiated Maxim Group Buy $50
Oct-26-12Reiterated Needham Buy $37 → $43
Oct-22-12Upgrade Canaccord Genuity Hold → Buy $45
Aug-08-12Reiterated Needham Buy $34 → $37
Jun-21-12Initiated Northland Securities Outperform $34
Oct-17-17 10:17AM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : October 17, 2017 Capital Cube
Oct-16-17 08:21AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : October 16, 2017 Capital Cube
Oct-12-17 04:05PM  SPS Commerce Announces Date of Third Quarter 2017 Financial Results GlobeNewswire
Oct-02-17 02:42PM  Should You Be Concerned About SPS Commerce Incs (SPSC) Risks? Simply Wall St.
Sep-15-17 08:02AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Sep-12-17 08:03AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Sep-07-17 09:04AM  Avis Budget's Zipcar Enters Latin America Through Costa Rica Zacks
Sep-06-17 08:01AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Sep-05-17 08:01AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Aug-29-17 09:07AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : August 29, 2017 Capital Cube
Aug-23-17 10:00AM  SPS Commerce Releases Integrated Fulfillment for Acumatica GlobeNewswire
Aug-18-17 07:40AM  ABM Industries Augments UK Footprint With Key Contract Wins Zacks
Aug-14-17 08:02AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Aug-11-17 11:10PM  Edited Transcript of SPSC earnings conference call or presentation 27-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
08:07AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Aug-01-17 04:05PM  SPS Commerce to Present at the Oppenheimer 20th Annual Technology, Internet & Communications Conference GlobeNewswire
11:58AM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube
Jul-31-17 07:42PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : July 31, 2017 Capital Cube
Jul-27-17 04:05PM  SPS Commerce Reports Second Quarter 2017 Financial Results GlobeNewswire
11:30AM  Investor Network: SPS Commerce, Inc. to Host Earnings Call ACCESSWIRE
Jul-14-17 09:14AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : July 14, 2017 Capital Cube
Jul-13-17 04:05PM  SPS Commerce Announces Date of Second Quarter 2017 Financial Results GlobeNewswire
Jul-11-17 03:03PM  ETFs with exposure to SPS Commerce, Inc. : July 11, 2017 Capital Cube
Jun-29-17 09:10AM  ABM to Save $13.7 Million in Energy Costs for Newton County Zacks
Jun-27-17 03:46PM  ETFs with exposure to SPS Commerce, Inc. : June 27, 2017 Capital Cube
08:45AM  Avis Budget Collaborates with Waymo for Self-Driving Cars Zacks
Jun-26-17 02:58PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 26, 2017 Capital Cube
May-30-17 09:00AM  SPS Commerce Announces Schedule of Upcoming Investor Conferences GlobeNewswire
May-16-17 09:11AM  Xerox Strengthens Foothold in Multi-Brand Retail Space Zacks
May-01-17 10:15AM  SPS Commerce Announces Comprehensive, Multi-Channel Demand Visibility for Retailing GlobeNewswire
10:15AM  SPS Commerce Ushers in New Era of Digital Product Data Management with Next Generation Assortment GlobeNewswire
09:00AM  SPS Commerce Unveils Enhanced Sourcing with Increased Visibility for Unified Retail Success GlobeNewswire
Apr-30-17 08:26AM  Edited Transcript of SPSC earnings conference call or presentation 27-Apr-17 8:30pm GMT Thomson Reuters StreetEvents
Apr-28-17 04:17PM  ETFs with exposure to SPS Commerce, Inc. : April 28, 2017 Capital Cube
Apr-27-17 06:20PM  SPS Commerce beats Street 1Q forecasts Associated Press
05:14PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : April 27, 2017 Capital Cube
04:05PM  SPS Commerce Reports First Quarter 2017 Financial Results GlobeNewswire
10:50AM  Investor Network: SPS Commerce, Inc. to Host Earnings Call Accesswire
Apr-26-17 09:20AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : April 26, 2017 Capital Cube
Apr-13-17 04:05PM  SPS Commerce Announces Date of First Quarter 2017 Financial Results GlobeNewswire
Apr-12-17 09:00AM  Beyond Now: Retail Leaders to Share Insights on Todays Retail Transformation at SPS Commerce In:fluence 2017 GlobeNewswire
Apr-04-17 09:00AM  Retail Leaders Unite to Move Beyond Omnichannel at SPS Commerce In:fluence 2017 GlobeNewswire
09:00AM  Retail Leaders Unite to Move Beyond Omnichannel at SPS Commerce In:fluence 2017
Mar-03-17 01:04PM  SPS COMMERCE INC Financials
Feb-27-17 05:26PM  SPS COMMERCE INC Files SEC form 10-K, Annual Report
Feb-21-17 09:00AM  SPS Commerce to Present at the JMP Securities 2017 Technology Conference GlobeNewswire
Feb-15-17 04:26PM  SPS COMMERCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Feb-09-17 12:17PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017 Capital Cube
12:17PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017
Feb-08-17 12:42PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 -18.86%
07:12AM  SPS Commerce downgraded by Pacific Crest and Canaccord Genuity
Feb-07-17 08:05PM  Edited Transcript of SPSC earnings conference call or presentation 7-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
08:05PM  Edited Transcript of SPSC earnings conference call or presentation 7-Feb-17 9:30pm GMT
06:23PM  SPS Commerce beats Street 4Q forecasts Associated Press
04:08PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 SPS Commerce Inc Earnings Release - After Market Close
Feb-01-17 03:03PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : February 1, 2017 Capital Cube
03:03PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : February 1, 2017
Jan-31-17 10:13AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : January 31, 2017 Capital Cube
10:13AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : January 31, 2017
Jan-26-17 02:20PM  More Retailers Get on Board With 'Drop Shipping' for E-Commerce The Wall Street Journal
02:20PM  More Retailers Get on Board With 'Drop Shipping' for E-Commerce at The Wall Street Journal
Jan-24-17 09:00AM  SPS Commerce In:fluence 2017 Empowers Attendees to Go Beyond with Inspirational Keynote Speakers GlobeNewswire
Jan-17-17 04:05PM  SPS Commerce Announces Date of Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Jan-16-17 08:00AM  Retail Industry Moving Beyond Omnichannel as Consumers Demand Personalized Shopping Experiences Across Channels GlobeNewswire
Jan-10-17 09:10AM  SPS Commerce and Deposco Deliver Orchestrated Retail Solutions to Advance the Digital Supply Chain GlobeNewswire
Jan-03-17 04:05PM  SPS Commerce to Present at the 19th Annual Needham Growth Conference GlobeNewswire
Dec-21-16 06:57AM  Avis Closes France Cars Buyout to Boost Global Presence
Dec-19-16 08:35AM  Xerox's (XRX) Strategic Efforts Bode Well, Risks Remain
Dec-12-16 02:35AM  SPS Commerce, Inc. (SPSC): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-02-16 11:06AM  ETFs with exposure to SPS Commerce, Inc. : December 2, 2016
Dec-01-16 07:16AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : December 1, 2016
Nov-10-16 09:30AM  Zacks.com featured highlights: SPS Commerce, CryoLife, FormFactor, Willdan Group and LegacyTexas Financial Group
Nov-09-16 08:01AM  Focus On 5 Best Profitable Stocks for Desirable Returns
Nov-04-16 09:30AM  Zacks.com featured highlights: Activision Blizzard, Gibraltar Industries, Northrop Grumman, SJW and SPS Commerce
Nov-03-16 10:15AM  Follow Driehaus' Rule & Pick These 5 Momentum Stocks
Oct-28-16 07:17PM  Edited Transcript of SPSC earnings conference call or presentation 27-Oct-16 8:30pm GMT -7.22%
04:05PM  SPS COMMERCE INC Files SEC form 10-Q, Quarterly Report
Oct-27-16 07:05PM  SPS Commerce tops Street 3Q forecasts AP
04:09PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 SPS Commerce Inc Earnings Release - After Market Close
Oct-26-16 09:14AM  Business Service Stocks Earnings on Oct 27: EXLS, FCN & More
Oct-25-16 05:05PM  Breakout Watch: RealPage Rallies Into Buy Zone Ahead Of Earnings
Oct-21-16 08:51AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : October 21, 2016
Oct-06-16 04:05PM  SPS Commerce Announces Date of Third Quarter 2016 Financial Results GlobeNewswire
Sep-30-16 04:54PM  Four Top Software Stocks That Are Tough To Top
Sep-22-16 08:35AM  SPS Commerce (SPSC) in Focus: Stock Jumps 6.5% in Session
Sep-21-16 12:30AM  IHS Tears Down the iPhone 7, Mast Therapeutics Crashes On Trial Failure, Plus the Latest Hype On 3 Other Stocks at Insider Monkey +6.53%
Sep-20-16 06:14PM  The Cooper Companies Set to Join the S&P 500; Northwestern and NuVasive to Join S&P MidCap 400; SPS Commerce and Fox Factory to Join S&P SmallCap 600 PR Newswire
Sep-19-16 10:46AM  ETFs with exposure to SPS Commerce, Inc. : September 19, 2016
Sep-16-16 09:29AM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016
Aug-03-16 04:05PM  SPS Commerce Announces Schedule of Upcoming Investor Conferences GlobeNewswire
09:24AM  Avis (CAR) Q2 Earnings Miss, Stock Up on Raised 2016 View
Jul-29-16 04:23PM  SPS COMMERCE INC Files SEC form 10-Q, Quarterly Report
Jul-28-16 08:11AM  Edited Transcript of SPSC earnings conference call or presentation 27-Jul-16 8:30pm GMT
07:25AM  SPS Commerce tops Street 2Q forecasts AP
Jul-27-16 04:08PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Second Quarter 2016 Financial Results GlobeNewswire
SPS Commerce, Inc. provides cloud-based supply chain management solutions worldwide. It provides solutions through the SPS Commerce platform, a cloud-based product suite that enhances the way suppliers, retailers, distributors, logistics firms, and other trading partners manage and fulfill orders. The company offers Trading Partner Fulfillment solution, which provides fulfillment automation and replaces or augments an organization's existing trading partner electronic communication infrastructure; Trading Partner Analytics solution that comprises data analytics applications to enhance visibility and analysis of customers supply chains; and Trading Partner Assortment solution to manage individual attributes associated with each item a retailer or supplier sells. It also provides Trading Partner Sourcing solution that enables retailers to source providers of new items, suppliers to connect with new retailers, and retailing community to make connections for expanding their business networks and grow; Trading Partner Community Development solution, which offers communications programs that enables retailers, suppliers, and emerging providers of value-added products and services to establish trading partner relationships with new trading partners to expand their businesses; and Other Trading Partner Solutions, such as barcode labeling, planogram services, and scan and pack application that helps trading partners process information to streamline the picking and packaging process. The company sells its solutions primarily through retail sales professionals and supplier sales representatives to small- to mid-sized suppliers in the consumer packaged goods industry, as well as retailers, distributors, third-party logistics providers, and other trading partners. The company was formerly known as St. Paul Software, Inc. and changed its name to SPS Commerce, Inc. in May 2001. SPS Commerce, Inc. was incorporated in 1987 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smerklo Michael ADirectorAug 29Sale61.3822713,933682Aug 31 05:32 PM
Smerklo Michael ADirectorJun 01Sale59.3776045,119909Jun 05 05:10 PM
Black Archie C.CEOMar 01Option Exercise16.6415,000249,600103,380Mar 03 06:05 PM
Black Archie C.CEOMar 01Sale55.8715,000837,99488,380Mar 03 06:05 PM
Frome James J.EVP & Chief Operating OfficerFeb 10Sale58.014,618267,88312,993Feb 14 08:10 PM
Frome James J.EVP & Chief Operating OfficerFeb 06Sale66.972,859191,46617,611Feb 08 05:18 PM
Black Archie C.CEOFeb 02Option Exercise16.645,37189,37373,971Feb 03 05:36 PM
Black Archie C.CEOFeb 02Sale68.135,371365,90368,600Feb 03 05:36 PM
Black Archie C.CEOFeb 01Option Exercise16.649,629160,22778,229Feb 03 05:36 PM
Black Archie C.CEOFeb 01Sale68.059,629655,23068,600Feb 03 05:36 PM
Black Archie C.CEOJan 04Option Exercise16.641,38523,04669,985Jan 05 05:26 PM
Black Archie C.CEOJan 04Sale70.031,38596,99568,600Jan 05 05:26 PM
Black Archie C.CEOJan 03Option Exercise16.6413,615226,55482,215Jan 05 05:26 PM
Black Archie C.CEOJan 03Sale69.2013,615942,11968,600Jan 05 05:26 PM
SORAN PHILIPDirectorNov 16Option Exercise27.552,67273,6147,938Nov 18 05:26 PM
SORAN PHILIPDirectorNov 16Sale66.282,672177,1025,266Nov 18 05:26 PM
Frome James J.EVP & Chief Operating OfficerNov 02Option Exercise25.323,94599,88724,415Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 02Sale62.193,945245,34120,470Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 01Option Exercise25.3212,023304,42232,493Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 01Sale62.2512,023748,47020,470Nov 03 05:11 PM
CRME Cardiome Pharma Corp. daily Stock Chart
CRME [NASD]
Cardiome Pharma Corp.
Index- P/E- EPS (ttm)-0.82 Insider Own0.80% Shs Outstand34.39M Perf Week-9.60%
Market Cap61.56M Forward P/E- EPS next Y-0.42 Insider Trans0.00% Shs Float32.95M Perf Month-17.70%
Income-25.70M PEG- EPS next Q-0.18 Inst Own76.60% Short Float0.39% Perf Quarter-61.67%
Sales23.20M P/S2.65 EPS this Y42.20% Inst Trans-0.22% Short Ratio0.90 Perf Half Y-43.35%
Book/sh0.89 P/B2.01 EPS next Y39.10% ROA-38.30% Target Price6.63 Perf Year-41.31%
Cash/sh0.83 P/C2.17 EPS next 5Y28.00% ROE-78.50% 52W Range1.81 - 4.84 Perf YTD-35.14%
Dividend- P/FCF- EPS past 5Y19.40% ROI-30.20% 52W High-63.02% Beta0.96
Dividend %- Quick Ratio4.10 Sales past 5Y75.80% Gross Margin71.70% 52W Low-1.10% ATR0.09
Employees120 Current Ratio4.80 Sales Q/Q-1.70% Oper. Margin-89.60% RSI (14)25.38 Volatility6.34% 4.70%
OptionableYes Debt/Eq0.00 EPS Q/Q28.90% Profit Margin- Rel Volume0.64 Prev Close1.85
ShortableYes LT Debt/Eq0.98 EarningsNov 07 AMC Payout- Avg Volume141.91K Price1.79
Recom2.00 SMA20-12.24% SMA50-26.81% SMA200-44.76% Volume90,900 Change-3.24%
Jul-17-17Resumed Canaccord Genuity Buy $8
Dec-22-16Initiated Leerink Partners Outperform
Jun-01-16Initiated H.C. Wainwright Buy $9.50
Jan-08-15Initiated Brean Capital Buy $13
Jan-07-14Initiated R. F. Lafferty Buy $9
Mar-20-12Downgrade RBC Capital Mkts Outperform → Sector Perform $6 → $1.50
Apr-27-11Upgrade RBC Capital Mkts Sector Perform → Outperform $8
Dec-08-10Initiated Wedbush Outperform $8.50
Oct-22-10Reiterated RBC Capital Mkts Sector Perform $10 → $9
Jun-23-10Reiterated UBS Buy $8.80 → $10.75
Aug-12-09Reiterated RBC Capital Mkts Sector Perform $11.50 → $9
Mar-19-09Reiterated Leerink Swann Outperform $8 → $6
Dec-01-08Reiterated Oppenheimer Outperform $18 → $15
Nov-17-08Reiterated Leerink Swann Outperform $15 → $8
Aug-12-08Reiterated RBC Capital Mkts Sector Perform $13.50 → $11.50
Aug-12-08Reiterated Lehman Brothers Equal-Weight $10 → $8
Jul-16-08Downgrade RBC Capital Mkts Outperform → Sector Perform $13.50
Mar-20-08Initiated Wachovia Outperform
Mar-11-08Initiated BMO Capital Markets Market Perform
Oct-09-07Initiated Lehman Brothers Equal-weight
Sep-13-17 11:33AM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
Sep-12-17 07:00AM  Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel PR Newswire
Sep-06-17 08:30AM  Cardiome, Pipeline Offers Opportunities Beyond Brinavess ACCESSWIRE
Sep-05-17 08:00AM  Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference CNW Group
Aug-30-17 08:00AM  New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS® PR Newswire
08:00AM  New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS® CNW Group
Aug-25-17 08:49AM  What Falling Estimates & Price Mean for Cardiome (CRME) Zacks
07:22AM  Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug Zacks
Aug-21-17 08:00AM  Cardiome Provides U.S. Regulatory Update For BRINAVESS PR Newswire -32.82%
Aug-08-17 11:55PM  Cardiome reports 2Q loss Associated Press
04:00PM  Cardiome Reports Second Quarter 2017 Financial Results PR Newswire
10:40AM  Investor Network: Cardiome Pharma Corp. to Host Earnings Call ACCESSWIRE
Aug-01-17 08:00AM  Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8 CNW Group
Jul-17-17 08:00AM  Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen PR Newswire
Jul-04-17 09:16AM  Cardiome's Partner SteadyMed Submits NDA for PAH Injection Zacks
Jul-03-17 08:00AM  Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension PR Newswire
Jun-23-17 08:00AM  Cardiome Pharma Corp. Announces Voting Results PR Newswire
08:00AM  Cardiome Pharma Corp. Announces Voting Results CNW Group
Jun-21-17 08:00AM  Cardiome Announces Licensing Agreement for XYDALBA (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel PR Newswire
Jun-12-17 07:30AM  Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada PR Newswire
07:30AM  Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada CNW Group
May-19-17 10:22AM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube
May-18-17 08:20AM  Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher Zacks +15.15%
May-17-17 09:59AM  Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss Zacks +6.14%
May-16-17 08:00AM  Cardiome Reports Changes To Senior Management Team CNW Group
May-15-17 04:18PM  Cardiome reports 1Q loss Associated Press
04:00PM  Cardiome Reports First Quarter 2017 Financial Results CNW Group
02:30PM  Investor Network: Cardiome Pharma Corp. to Host Earnings Call Accesswire
08:00AM  Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds PR Newswire
08:00AM  Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds CNW Group
May-08-17 08:00AM  Cardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15 CNW Group
Apr-27-17 08:00AM  Cardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference PR Newswire
Apr-10-17 08:45AM  Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session Zacks
Apr-06-17 08:00AM  Cardiome's Partner SteadyMed Announces Successful Completion of Trevyent® Clinical Validation Study PR Newswire
Apr-03-17 08:00AM  Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review PR Newswire
Apr-01-17 01:04PM  CARDIOME PHARMA CORP Financials
Mar-31-17 08:00AM  Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors GlobeNewswire
Mar-20-17 09:04AM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
Mar-16-17 09:55AM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
Mar-14-17 03:02PM  Cardiome Receives Notice of Compliance from Health Canada for its BRINAVESS NDS PR Newswire
03:02PM  Cardiome Receives Notice of Compliance from Health Canada for its BRINAVESS NDS CNW Group
Mar-07-17 04:20PM  Cardiome reports 4Q loss Associated Press
04:00PM  Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
04:00PM  Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results CNW Group
Mar-03-17 08:00AM  Cardiome Announces Commercial Launch of Xydalba (dalbavancin) in France PR Newswire
Feb-27-17 08:00AM  Cardiome To Hold Fourth Quarter And Full Year 2016 Financial Results Conference Call On March 7 PR Newswire
08:00AM  Cardiome To Hold Fourth Quarter And Full Year 2016 Financial Results Conference Call On March 7 CNW Group
Dec-22-16 06:58AM  Coverage initiated on Cardiome Pharma by Leerink Partners
Dec-20-16 08:00AM  Cardiome Announces Commercial Launch of XYDALBA (dalbavancin) in Germany PR Newswire
Dec-13-16 07:04PM  Is CARDIOME PHARMA CORP (CRME) a Good Stock to Buy? at Insider Monkey
Dec-08-16 11:55AM  Cardiome Announces Commercial Launch of Xydalba (dalbavancin) in the UK PR Newswire
Nov-29-16 08:00AM  Cardiome Advances Toward the UK XYDALBA (dalbavancin) Launch PR Newswire
Nov-09-16 11:48AM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
Nov-07-16 08:12AM  Cardiome reports 3Q loss +9.80%
08:00AM  Cardiome Reports Third Quarter 2016 Financial Results PR Newswire
Nov-01-16 08:00AM  Cardiome to Reschedule Release of Third Quarter 2016 Financial Results PR Newswire
Oct-28-16 08:00AM  Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7 PR Newswire
Oct-26-16 09:14AM  New Strong Sell Stocks for October 26th
Oct-14-16 09:15AM  New Strong Sell Stocks for October 14th
08:00AM  Cardiome Announces Initiation of Commercial Operations in Canada, Eh PR Newswire
Aug-16-16 08:00AM  Cardiome Announces Recent Insider Purchases PR Newswire
Aug-11-16 10:44AM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
Aug-09-16 04:47PM  Cardiome reports 2Q loss
04:00PM  Cardiome Reports Second Quarter 2016 Financial Results PR Newswire
04:00PM  Cardiome Announces XYDALBA Single Dose Infusion Approval by European Medicines Agency PR Newswire
Aug-08-16 08:00AM  Cardiome Announces the Addition of Two Key Members to its Management Team PR Newswire
Aug-03-16 04:30PM  Cardiome to Hold Second Quarter 2016 Financial Results Conference Call on August 9 PR Newswire
Jul-29-16 09:53AM  Cardiome Closes Public Offering of 11,500,000 Common Shares PR Newswire
Jul-27-16 04:04PM  New York Community Bank Drops in on Wednesdays 52-Week Low Club at 24/7 Wall St.
Jul-26-16 04:08PM  Noodles, Cardiome Lead Tuesdays 52-Week Low Club at 24/7 Wall St. -43.21%
08:38AM  Cardiome Announces Pricing of Public Offering of 10,000,000 Common Shares PR Newswire
Jul-25-16 04:01PM  Cardiome Announces Proposed Public Offering of Common Shares PR Newswire
Jul-18-16 08:00AM  Ionis Pharmaceuticals (IONS) in Focus: Stock Soars 11.3%
Jul-14-16 08:00AM  ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimbursement in Italy PR Newswire
Jun-24-16 08:00AM  Cardiome Pharma Corp. Announces Voting Results PR Newswire
Jun-14-16 08:00AM  Cardiome Announces Term Loan Agreement with CRG-Managed Funds PR Newswire
Jun-04-16 11:25AM  2 Small-Cap Speculative Biohealth Stocks Called to Double or Rise Exponentially at 24/7 Wall St.
May-23-16 01:23PM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016
08:25AM  Cardiome Pharma (CRME) Jumps: Stock Moves 8.1% Higher
May-13-16 07:11AM  Cardiome reports 1Q loss
07:00AM  Cardiome Reports First Quarter 2016 Financial Results PR Newswire
May-12-16 08:00AM  Cardiome Announces the Launch of ESMOCARD Solution for Injection in France PR Newswire
May-11-16 08:00AM  Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 PR Newswire
08:00AM  Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study PR Newswire
May-10-16 09:45AM  Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More Zacks
May-05-16 04:15PM  Cardiome and Allergan Announce XYDALBA (Dalbavancin) Licensing Agreement in International Markets PR Newswire
Apr-28-16 08:00AM  Cardiome to Present at the Bloom Burton & Co. 5th Annual Healthcare Investor Conference PR Newswire
Apr-25-16 09:16AM  New Strong Sell Stocks for April 25th Zacks -5.23%
Apr-21-16 06:30PM  A Closer Look Into Veritas Pharma Gurufocus
Apr-14-16 08:51AM  New Strong Sell Stocks for April 14th
Mar-31-16 08:00AM  Cardiome Announces Publication of Independent Study Comparing BRINAVESS to Ibutilide in Patients with Recent-Onset Atrial Fibrillation PR Newswire
Mar-29-16 09:07AM  New Strong Sell Stocks for March 29th +7.00%
Mar-24-16 08:47AM  New Strong Sell Stocks for March 24th
Mar-23-16 02:54PM  Fairholme Cuts Stake in Sears Holdings Corp (SHLD), Ubben Sells Even More Shares of Motorola Solutions Inc. (MSI), Plus Two Other Moves at Insider Monkey
Mar-21-16 01:25PM  Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q4, 2015 By the Numbers
10:05AM  New Strong Sell Stocks for March 21st
Mar-10-16 07:27AM  Cardiome reports 4Q loss
07:00AM  Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results PR Newswire
Mar-07-16 05:53PM  Cardiome Announces Filing of Prospectus Supplements PR Newswire
Mar-04-16 03:24PM  Cardiome To Hold Fourth Quarter And Full Year 2015 Financial Results Conference Call On March 10 PR Newswire +6.16%
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.